联系我们
BioCon China 2021 第八届国际生物药大会暨生物技术仪器设备与试剂展览会

微信扫码立即联系主办方

微信分享
BioCon China 2021 第八届国际生物药大会暨生物技术仪器设备与试剂展览会

使用微信扫一扫分享到朋友圈

活动分享
BioCon China 2021 第八届国际生物药大会暨生物技术仪器设备与试剂展览会

使用微信扫一扫进入小程序分享活动

大会背景

随着审评、审批速度大大加快、市场准入规则逐渐清晰,尤其在新冠疫情的影响下,临床上对生物药的需求日益迫切,生物药已经成为世界经济的主导产业。然而,机遇与挑战并存。新药开发过于集中在个别热门靶点、生产成本居高不下、质量一致性难以维持、对于新型治疗手段缺乏统一的质量标准等问题,不仅是某一家生物药企业面临的问题,更是中国生物药产业必须克服的挑战。


作为中国生物药企业参与度最高的年度盛会,BioCon 2021第八届国际生物药大会暨生物技术仪器设备与试剂展览会将于2021年4月22-23日在上海宝华万豪酒店崭新升级上线,更高质量、更深层次,紧抓全球生物药最新风向标,将围绕下一代双多抗ADC抗体偶联细胞与基因治疗制品溶瘤病毒制品核酸疫苗与药物等品类,聚焦最新法规监管趋势深度剖析生物药前沿开发策略从新靶点药物发现与设计智能/连续化/自动化工艺开发与优化降本增效卓越生产运营到生物药报产市场准入与商业化布局等全流程,为中国生物医药产业搭建国内外政策研讨、技术交流、产品展示、项目合作的综合性专业平台,共探行业核心趋势,推动生物医药产业全速前进!


七大板块.png

BioCon 2021 新亮点

  7+专场论坛,100+精彩报告,深入探讨国内外生物药企最关心的热点与挑战

  解读最新国内外法规动向,剖析中国审评、市场准入政策,助力加速企业研发与产品上市

  聚焦热点药品品类——下一代双多抗、ADC抗体偶联、细胞与基因治疗制品、溶瘤病毒制品、核酸疫苗与药物等药学与工艺开发、优化,加快产业化

  交流最新生物药物靶点发现,技术平台与医学转化临床案例分享

  解析蛋白/抗体/细胞药物商业化报产、现场核查、上市后变更等重点难点

★  聚焦降本增效的卓越生产运营,未来4.0工厂建设与应用,及连续化生产的质量控制与管理

BioCon 2021 重磅嘉宾(按首字母排序)
  • 武田(美国)细胞治疗分析开发负责人
  • 西美杰科技研发副总裁
  • 美国药典生物部门副总裁
  • 合源生物CTO,前诺华全球质量官
  • 和铂医药CMC负责人
  • 南京金斯瑞生物科技有限公司高级科学家
  • 拓创生物首席科学官
  • 前FDA审评主任,生物制品,药学
  • 启德医药CSO
  • EMA 生物制品工作组主席;EMA CAT前沿治疗委员会西班牙主席;西班牙药监局生物药与前沿疗法负责人
  • BioGENEEXUS, LLC创始人兼CEO
  • 百奥泰生产运营高级总监
  • 武汉博威德生物技术有限公司董事长兼首席科学家
    Male, Doctor of Medicine, Histology and Embryology, Tongji Medical College, Huazhong University of Science and Technology. In 2018, it was awarded the title of "Labor Model of Hubei Province" by the Hubei Federation of Trade Unions. He has been engaged in teaching and scientific research for many years in universities and served as the executive director of Hubei Biochemical Society and Molecular Biology Society. He is good at industrializing high-tech achievements in biology. In September 2010, Dr. Cai set up Wuhan Bwd Biotech Biotechnology Co., Ltd. and began to devote himself to the research of virus and anti-cancer. On January 21, 2015, Dr. Cai won a patent for the invention of a coxsackievirus and its application of anti-cancer drugs. In the same year, Dr. Cai obtained the eighth batch of 3551 talents from Wuhan Dong Hu Hi-tech Co., Ltd.
  • 合生基因CEO
  • 博奥信生物技术(南京)有限公司创始人、总裁
  • 德晟济医药创始人
  • 中吉智药(南京)生物技术有限公司创始人,首席科学家
  • 南京艾美斐生物科技有限公司创始人、首席执行官
  • 南京传奇生物联合创始人,首席科学官

    Dr. Fan Xiaohu is a well-known expert in the field of Applied Immunology and gene therapy. In 2004, he made a major breakthrough in the basic research of the mechanism of children's blood group incompatibility with heart transplantation. In his original paper published by Nature Medicine, he clarified the mechanism of immune tolerance in the process of children's heart transplantation and demonstrated that infant patients need not consider A before transplantation. BO blood group matched. This achievement breaks the limitation of homogenous organ transplantation and greatly improves the chances of organ transplantation for children with diseases. Returning to China in 2014 and joining Kingsley Group, Kingsley subsidiary Nanjing Legendary Biology was founded in early 2015. Excellent R&D team was established and advanced CAR-T technology platform was independently developed. LCAR-B38M, the first product for the treatment of relapsed and refractory multiple myeloma, achieved international leading results. Since its use in clinical trials in 2016, 74 people have been treated, with a complete response rate of 75%. This product has won a strategic partnership agreement between Johnson & Johnson and Legend to develop the global market for this product. On March 8, 2018, LCAR-B38M products were awarded the first clinical trial approval of CAR-T cell drugs in China, which became an important milestone in the history of cell therapy drugs in China. On May 30, 2018, LCAR-B38M products were also approved by the US FDA for phase Ib/II clinical trials. In 2019, he was eligible for the EU EMA Priority Drug Review. At present, Legendary Biology has the world's largest cell drug research and development team, developed a large number of new CAR-T cancer treatment products and a number of innovative intellectual property platform technology.

  • 荣昌生物制药首席科学官
  • 荣昌生物制药有限公司总裁
  • 信达生物首席技术官/高级副总裁
  • Sorrento Therapeutics Inc, CTO, Cell Therapy
  • 阿斯利康全球研发中国中心总裁
  • 默克BioReliance End-to-End 亚太区GMP生产负责人
  • 德祥科技资深产品经理
  • 美雅珂生物董事长兼首席执行官
  • 亿腾医药总监
  • 复旦大学公共卫生学院教授
  • 熙宁生物中国区总经理
  • 蔻德罕见病中心(CORD,原罕见病发展中心)创始人、主任
  • 复宏汉霖高级副总裁兼首席运营官
  • 达博生物董事长兼CEO
  • 百奥泰抗体发现副总裁
  • 北京因美未来生物医药科技有限公司创始人兼董事长
  • 南京传奇生物科技有限公司高级注册总监
  • 复宏汉霖联合创始人兼CSO
  • 信达生物副总裁
  • 维立志博执行副总裁

    In the mid-1990s, Dr. Lai Shoupeng carried out postdoctoral research on cancer immunotherapy in Steven Rosenburg Laboratory, Director of Surgery, National Cancer Institute of the United States. After entering the biomedical industry, he has been engaged in research and development of new biological drugs for more than 20 years. He has accumulated rich experience in biopharmaceutical technology development, GMP production and project management. In 2014, Nanjing leadsbiolabs Co., Ltd. was co-founded, focusing on the development of new anti-cancer drugs for immunotherapy.

  • 上海市免疫学研究所副所长
  • 斯微生物创始人兼CEO
  • 迈博药业副总裁
  • 基石药业首席技术官
  • 百济神州高级副总裁,生物药研发负责人
    Graduated from Emory University, Atlanta, Georgia, in 1990, with PhD in Biochemistry and Molecular Biology. Worked in biomedical research and pharmaceutical drug discovery since 1990, with long term focus on cancer biology, immuno-oncology, antibody engineering technology and cancer drug discovery, as well as mitochondrial energy metabolism and apoptosis, and work experience with Tanox and Pfizer (La Jolla Lab). Fruitful in the field of research pursued, with many publications as first author or corresponding author in scientific magazines such as Cell, Journal of Biochemistry, Cancer Immunology and Immunotherapy, Journal of Cell Biology. Registered and granted with over 20 patented inventions worldwide.
  • 君实生物CEO
  • 安源医药创始人、董事长
  • 天境生物工程与技术副总裁
  • 恒瑞源正CMO
  • 药明巨诺联合创始人兼CEO
  • 泰诺麦博COO
  • 厦门诺康得生物科技有限公司创始人、董事长兼CEO
    Founder of Xiamen NKD Biotechnology Co., Ltd., visiting scholar of Michigan State University, doctor of chemical biology of Xiamen University. Long-term commitment to biomedical research, has a senior research in the field of new drug research and development in glycochemistry.
  • 荣昌生物制药(烟台)生物有限公司副总裁、总工程师
  • 上海锦斯生物创始人/总经理,上海大学生命科学学院教授
  • 中国抗体创办人兼CEO
  • 滨会生物董事长
  • 华东医药首席科学官
  • 百济神州生物岛创新中心首席执行官
  • 齐鲁制药集团副总裁
  • 礼来公司生物技术发现研究团队首席科学家
  • 康源久远创始人
  • 恒瑞医药副总经理
  • 上海臻上医药科技有限公司高级总监
  • 科望医药联合创始人兼首席科学官
  • 星尘生物科技(上海)有限公司联合创始人、首席科学官
  • 圣诺制药创始人、董事长兼总裁
  • 纽福斯生物CEO
  • 广州百暨基因科技有限公司首席技术官
  • 伯乐生命医学产品公司市场部产品经理
  • 合源生物CEO
    Dr. Lu received his doctor's degree in clinical medicine (hematology) in 2006. He has seven years'experience as a clinical doctor. Before 2007, Dr. Lu mainly engaged in clinical and scientific research of hematopoietic stem cells and mesenchymal stem cells. In 2001, he participated in the completion of the first umbilical cord blood transplantation for the treatment of childhood leukemia in China. In 2004, he established the separation technology of umbilical cord mesenchymal stem cells for the first time in China. In 2005, he went to Westchester Medical Center of New York Medical College of the United States to continue to work on hematopoietic cell transplantation and mesenchymal stem cell research. Several papers were published in international and domestic Dr. Lu joined multinational pharmaceutical companies in 2007 and has been engaged in research and development of innovative drugs and strategic planning for new products in the field of blood and cancer for more than 10 years. He has worked in key positions of multinational companies such as Novartis, Jianzan, Roche, AstraZeneca and Merceton. He has rich research and development in targeted drugs, immunotherapy and cell therapy. Experience in product life cycle management. It plays an important role in the registration, R&D and market expansion of epoch-making cancer products such as Gleevey, Herceptin, Teresa and Coreda. In June 2018, Dr. Lu left the multinational pharmaceutical enterprises and joined the ranks of domestic innovative drug research and development. Now as CEO of Heyuan Biotechnology (Tianjin) Co., Ltd., we are committed to promoting the progress of basic and clinical research of cell therapy in China, promoting the industrialization process of cell therapy, building the leading cell therapy products in the world and saving the lives of blood and cancer patients.
  • 尚健生物创始人兼CEO
  • 上海漕河泾奉贤科技绿洲建设发展有限公司生物医药产业发展首席顾问
  • 弗若斯特沙利文合伙人
  • 亦诺微医药首席研发官/临床总监
  • 迈威(上海)生物科技股份有限公司副总裁
  • 丽凡达生物CEO
  • 北京艺妙神州医药科技有限公司联合创始人、CTO
    Feifei Qi, Ph.D. is the CTO and co-founder of Immunochina Pharmaceuticals, developing best-in-class genetically engineered cell products for oncology indications, where he oversees the CMC activities for all next generation immune cell therapies. He received his Ph.D. in Biology at School of Life Sciences, Tsinghua University in 2015. He has over 10 years of research experience in cancer immunotherapy, and 5 years of experience in process development and quality analysis for cell & gene therapy products.
  • 天境生物药学副总裁
  • 美雅珂生物高级副总经理
  • 启愈生物创始人
  • 苏州茂行生物科技有限公司创始人、CEO
  • 上海乐纯生物技术有限公司市场技术副总裁
  • 上海优替济生生物医药有限公司首席执行官
  • 岸迈生物CMC高级副总裁
  • 深圳裕策生物高级副总裁兼裕泰抗原事业部总经理
  • 上海细胞治疗集团有限公司副总裁兼细胞药物BU总经理
    The vice president of Shanghai Cell Therapy Group/general manager of drug transformation system is mainly engaged in drug transformation of cell therapy products, and carries out drug transformation research and registration declaration of the first domestic non-viral vector CAR-T products.
  • 宜明昂科董事长兼总经理
  • 志济生物创始人
  • 海正博锐生产副总监
  • 南京卡提医学科技有限公司创始人
  • 嘉因生物联合创始人兼CTO
  • 复星凯特总裁
    Richard received degrees of B.S of Cell Biology from the University of Science & Technology of China, Ph.D. of Molecular Biology from the University of Maryland, Baltimore and MBA from Xavier University, Cincinnati in the US. He obtained his postdoctoral training at the National Institutes of Health, Baltimore, USA. Richard now is the CEO of Fosun Kite Biotechnology . Taking a combined approach of internal R&D and external partnering/technology transfer, Fosun Kite is dedicated to the advancement of innovative cell therapy and its industrialization in China to benefit patients. Richard is very experienced in biopharmaceutical industry . Having spent close to 20 years in R&D and management positions in both the US and China, he has taken senior roles and increasing leadership responsibilities in Procter & Gamble Pharmaceutical, Bristol-Myers Squibb in the US, AstraZeneca Innovation Center and GSK R&D Center in China. Prior to Fosun Kite, Richard was the Chief Operation Officer of Cellular Biomedicine Group (NASDAQ: CBMG), where he was in charge of the company’s immunotherapy pipeline including manufacturing, clinical development and registration, and the stem cell business unit.
  • 武田亚洲研发中心负责人
  • 凡恩世总裁兼首席执行官
  • 玛丽女王伦敦大学肿瘤细胞与基因治疗首席教授
  • 天士力创世杰总经理
    Wang Zhiming, the CEO of Tasly (Tianjin) BioPharmaceutical Co., Ltd., which focuses on innovative gene therapy and oncolytic virus products development. He hosted the CMC development of two innovative therapeutic biologics, and leaded the non-clinical research, RA and clinical development of the two biologics. He has more than 10 years work experience in biologics period, covering preclinical, RA, clinical development, industrialization and commercialization production.
  • 岸迈生物CEO
  • 丹瑞生物CEO
  • 嘉因生物创始人
  • 浙江新码生物CSO
  • SAPA执行董事,英诺湖医药董事长兼CEO
  • BCG上海合伙人兼董事总经理
  • 康方生物高级副总裁
  • 和度生物创始人兼CEO
  • 优洛生物+首席科学家&执行副总
  • 纽福斯联合创始人兼CTO
  • 君实生物工程总经理
  • 深圳新诺微环生物医药科技有限公司总经理
  • 基石药业首席科学官,高级副总裁 研究及早期临床开发负责人
  • 康宁杰瑞总裁
  • 第一三共中国开发总经理
  • 苏州宜联创始人兼CEO
  • 百济神州高级副总裁、全球药政事务负责人
  • 再鼎医药首席运营官
  • 中山大学药理学教授,中山大学原副校长
  • 基石药业首席医学官
  • 开拓药业生物药研发副总裁
  • 前美国FDA医疗评审官
  • 齐鲁制药CSO
  • 艾博生物CEO
  • 上海恒瑞生物药研发执行总监
  • 美国AAVnerGene创始人、董事长和首席执行官
  • 四川安可康生物科技有限公司董事长,CEO,前FDA CMC审评员
  • 上海蓝鹊生物CEO
  • 亘喜生物科技集团质量副总裁
  • 杭州翰思生物医药有限公司董事长
  • 厚存纳米药业有限公司创始人兼CEO
  • 赛诺菲中国区工业事务部负责人
  • 宜明昂科副总经理
  • 腾盛博药临床科研执行总监
  • 天境生物总裁
  • 安进亚洲研发中心抗体研发主管
  • 天演药业首席生产官
  • 浙江海昶生物医药技术有限公司总裁,前FDA高级审评员
  • 前沿生物药业(南京)股份有限公司首席运营官
  • 上海交通大学讲席教授,细胞工程与抗体药物教育部工程研究中心主任
  • 阿思科力(苏州)生物科技有限公司工艺总监
  • 凡恩世首席科学官
  • 亿腾景昂CEO
  • 往期回顾

    wq3-01.png

    往届评价 往届评价
    BioCon China 2021 第八届国际生物药大会暨生物技术仪器设备与试剂展览会
    BioCon China 2021 第八届国际生物药大会暨生物技术仪器设备与试剂展览会
    BioCon China 2021 第八届国际生物药大会暨生物技术仪器设备与试剂展览会
    BioCon China 2021 第八届国际生物药大会暨生物技术仪器设备与试剂展览会
    BioCon China 2021 第八届国际生物药大会暨生物技术仪器设备与试剂展览会
    BioCon China 2021 第八届国际生物药大会暨生物技术仪器设备与试剂展览会
    活动门票
    活动筹备中
    售票推广中
    活动结束
    选择票
    门票名称
    单价(¥)
    截止时间
    数量
    A:高峰论坛票(闭门会)
    2,980
    2021-04-23 17:30
    已售罄
    B:通票
    3,980
    2021-04-23 17:30
    0
    此门票4张及以上赠送2张
    A+B
    4,980
    2021-04-23 17:30
    已售罄
    优惠或邀请码
    票价
    0
    找回电子票
    请输入您在报名时填写的手机号或者邮箱
    确定找回